Transient thyrotoxicosis during nivolumab treatment

Area of Science:

• Oncology
• Endocrinology
• Immunology

Background:

• Nivolumab, an immune checkpoint inhibitor, is widely used in cancer therapy.
• Immune-related adverse events (irAEs) are common side effects of nivolumab.
• Thyroid dysfunction is a known irAE associated with immune checkpoint inhibitors.

Observation:

• Two patients receiving nivolumab developed transient thyrotoxicosis.
• Thyrotoxicosis symptoms appeared 2-4 weeks after initiating nivolumab therapy.
• The thyrotoxicosis resolved and transitioned to hypothyroidism within 6-8 weeks.

Findings:

• Nivolumab-induced thyrotoxicosis can be a transient condition.
• A progression from thyrotoxicosis to hypothyroidism is observed in some patients.
• Early management with beta-blockers may be effective for symptomatic relief.

Implications:

• Clinicians should monitor thyroid function in patients treated with nivolumab.
• Understanding the temporal course of thyroid irAEs is crucial for patient management.
• This suggests a need for careful follow-up and potential intervention for thyroid dysfunction during nivolumab therapy.